|
UPRT expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.2929000092754E-09 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
3.78440000448066E-08 |
| Normal-vs-Stage2 |
5.324000E-03 |
| Normal-vs-Stage3 |
1.29480004495974E-09 |
| Normal-vs-Stage4 |
2.62169952414126E-10 |
| Stage1-vs-Stage2 |
1.027750E-01 |
| Stage1-vs-Stage3 |
1.094160E-02 |
| Stage1-vs-Stage4 |
4.518000E-03 |
| Stage2-vs-Stage3 |
3.316100E-03 |
| Stage2-vs-Stage4 |
5.955500E-04 |
| Stage3-vs-Stage4 |
4.845600E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
8.92574902877641E-12 |
| Normal-vs-AfricanAmerican |
1.414350E-02 |
| Normal-vs-Asian |
1.59941999999802E-05 |
| Caucasian-vs-AfricanAmerican |
7.182100E-02 |
| Caucasian-vs-Asian |
2.081400E-01 |
| AfricanAmerican-vs-Asian |
4.925200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
9.12389999996321E-07 |
| Normal-vs-Female |
8.317400101987E-10 |
| Male-vs-Female |
3.157600E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
5.71479999988966E-07 |
| Normal-vs-Age(41-60Yrs) |
4.97969998569658E-09 |
| Normal-vs-Age(61-80Yrs) |
3.5493999961389E-08 |
| Normal-vs-Age(81-100Yrs) |
6.044300E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
6.849600E-02 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.700850E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
1.552630E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
8.259400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
4.578000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
3.826200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
2.813800E-02 |
| Classical-VS-Follicular |
6.04159999999521E-05 |
| Classical-VS-Other |
7.916400E-01 |
| Classical-VS-Normal |
1.05300002051223E-09 |
| Tall-VS-Follicular |
1.19109999996425E-06 |
| Tall-VS-Other |
1.137640E-01 |
| Tall-VS-Normal |
5.52320000846152E-09 |
| Follicular-VS-Other |
3.120800E-01 |
| Follicular-VS-Normal |
2.105900E-02 |
| Other-VS-Normal |
3.449800E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.28040000046958E-07 |
| Normal-vs-N1 |
4.17000001196044E-09 |
| N0-vs-N1 |
3.782400E-02 |
|
|
